MISSY EDWARDS STRATEGIES, LLC for GENENTECH
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 16, 2015 | $30,000 | Replaced |
| 4th Quarter - Amendment | Jan 16, 2015 | $30,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 959, "Pharmaceutical Compounding Quality and Accounting Act" H.R. 1416, "Cancer Patient Protection Act of 2013" S. 957, "Drug Supply Chain Security" H.R. 1919, " Safeguarding America's Pharmaceuticals Act"
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA M EDWARDS | Legislative Assistant, US Senator Thad Cochran |
Budget/Appropriations BUD
Following issues related to the budget and appropriations process FY14 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA M EDWARDS | Legislative Assistant, US Senator Thad Cochran |
Taxation/Internal Revenue Code TAX
General tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned U.S. corporations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA M EDWARDS | Legislative Assistant, US Senator Thad Cochran |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.